Lantern Pharma to Advance EMA-Cleared Phase 1b/2 Trial of LP-184 (Zirdafulven) in Biomarker-Selected Advanced Bladder Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/7/2026

1. HUVR:IN
2. ANET
3. NKE
4. PANW
5. CL
6. SNDK
7. TAP
8. DELL
9. ROIV
10. EAT

Go back to Lantern Pharma to Advance EMA-Cleared Phase 1b/2 Trial of LP-184 (Zirdafulven) in Biomarker-Selected Advanced Bladder Cancer
(NASDAQ: LTRN) Delayed: 1.91 +0.04 (2.14%)
Previous Close $1.87    52 Week High $ 
Open $1.86    52 Week Low $ 
Day High $1.93    P/E N/A 
Day Low $1.83    EPS $ 
Volume 134,556